The disc replacement company turned a $10.2 million profit in the first half and plans to trade on the NYSE as CNTL.
Centinel Spine has filed for an initial public offering in the United States, reporting a 42% increase in revenue for the first half of 2026, according to Reuters. The West Chester, Pennsylvania, company has built its business entirely around total disc replacement (TDR), and the numbers in its registration statement suggest that bet is starting to pay off.
First-half results
Revenue for the six months ended June 30 rose to $85.2 million from $60.1 million in the prior-year period, an increase of about $25 million. Centinel also moved into the black. It booked net income of $10.2 million for the half, compared with a net loss of $503,000 a year earlier. The growth has been steady. In 2023, Centinel said prodisc revenue for the first six months of that year was about $32 million, up more than 50% on the prior year.
Built on prodisc
Centinel’s implants are designed to preserve motion at the treated level and are positioned as an alternative to spinal fusion, which permanently eliminates movement at that segment. According to the company, the prodisc platform has been used in more than 300,000 implantations worldwide and is supported by more than 590 peer-reviewed clinical papers.
Centinel bought the worldwide prodisc assets from DePuy Synthes in late 2017. The deal brought in prodisc C and prodisc L, which already had FDA premarket approval in the U.S. In 2023 the company sold its cervical and lumbar fusion portfolio, including the STALIF platform, to Silony Medical so it could concentrate on disc replacement. Centinel says prodisc is the only TDR system in the U.S. with FDA-approved two-level indications in both the cervical and lumbar spine.
Analyst view
IPOX research associate Lukas Muehlbauer told Reuters that the filing stands out for pairing strong revenue growth with profitability, something many healthcare companies coming to market cannot show. He cautioned, however, that Centinel’s exclusive focus on total disc replacement creates concentration risk, leaving the company exposed to changes in reimbursement policy and to competing technologies. Centinel makes the same point in its own filing. Among the risk factors in the S-1, the company states that it depends entirely on sales of prodisc products for its revenue.
Offering details
Centinel plans to list its shares on the New York Stock Exchange under the symbol CNTL. Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity and BTIG are underwriting the offering. Proceeds will go toward repaying debt and investing in the company’s sales infrastructure, patient-awareness programs and clinical trials, among other uses. The filing comes amid an uncertain fall IPO market. Rising bond yields and high interest rates have weighed on investor appetite, and several large companies have delayed their listings.
About Centinel Spine, LLC
Centinel Spine®, LLC is the leading global medical device company addressing cervical and lumbar spinal disease with the most clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®). The Company’s prodisc technology is the most studied and clinically-proven TDR system across the globe, validated by over 540 published papers and 250,000 implantations worldwide. Centinel Spine continues to advance its pioneering culture and corporate mission to become a catalyst of change in the spine industry and alter the way spine surgery is perceived. The prodisc platform remains the only technology with multiple motion-preserving solutions for both cervical and lumbar anterior column reconstruction. For more information, please visit the company’s website at www.CentinelSpine.com.